According to 2016 and 2022 guidelines, the WHO recognizes several novel histopathological features and prognostic factors for DLBCL, including cell-of-origin classification (germinal center vs. activated B-cell), CD5 expression, and quantification of c-MYC and BCL2 expression in lymphoma cells as assessed by immunohistochemistry, referred to as double expressor status [4–7]. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.